Evaluating dosimetric accuracy of the 6 MV calibration on EBT3 film in the use of Ir-192 high dose rate brachytherapy.

PURPOSE: To evaluate the dosimetric accuracy of EBT3 film calibrated with a 6 MV beam for high dose rate brachytherapy and propose a novel method for direct film calibration with an Ir-192 source. METHODS: The 6 MV calibration was performed in water on a linear accelerator (linac). The Ir-192 calibration was accomplished by irradiating the film wrapped around a cylinder applicator with an Ir-192 source. All films were scanned 1-day post-irradiation to acquire calibration curves for all three (red, blue, and green) channels. The Ir-192 calibration films were also used for single-dose comparison. Moreover, an independent test film under a H.A.M. applicator was irradiated and the 2D dose distribution was obtained separately for each calibration using the red channel data. Gamma analysis and point-by-point profile comparison were performed to evaluate the performance of both calibrations. The uncertainty budget for each calibration system was analyzed. RESULTS: The red channel had the best performance for both calibration systems in the single-dose comparison. We found a significant 4.89% difference from the reference for doses <250 cGy using the 6 MV calibration, while the difference was only 0.87% for doses >600 cGy. Gamma analysis of the 2D dose distribution showed the Ir-192 calibration had a higher passing rate of 91.9% for the 1 mm/2% criterion, compared to 83.5% for the 6 MV calibration. Most failing points were in the low-dose region (<200 cGy). The point-by-point profile comparison reported a discrepancy of 2%-3.6% between the Ir-192 and 6 MV calibrations in this low-dose region. The linac- and Ir-192-based dosimetry systems had an uncertainty of 4.1% (k = 2) and 5.66% (k = 2), respectively. CONCLUSIONS: Direct calibration of EBT3 films with an Ir-192 source is feasible and reliable, while the dosimetric accuracy of 6 MV calibration depends on the dose range. The Ir-192 calibration should be used when the measurement dose range is below 250 cGy.

Computed tomography-based flap brachytherapy for non-melanoma skin cancers of the face.

PURPOSE: Non-melanoma skin cancers of the face are at high-risk for local recurrence and metastatic spread. While surgical interventions such as Mohs microsurgery are considered the standard of care, this modality has the potential for high rates of toxicity in sensitive areas of the face. Catheter flap high-dose-rate (HDR) brachytherapy has shown promising results, with high rates of local control and acceptable cosmetic outcomes. MATERIAL AND METHODS: Patients with non-melanoma skin cancers (NMSC) located on the face were treated with 40 Gy in 8 fractions, given twice weekly via catheter flap HDR brachytherapy. Clinical target volume (CTV) included the visible tumor plus a margin of 5 mm in all directions, with no additional planning target volume (PTV) margin. RESULTS: Fifty patients with 53 lesions on the face were included, with a median follow-up of 15 months. All were considered high-risk based on NCCN guidelines. Median tumor size and thickness were 18 mm and 5 mm, respectively. Median PTV volume and D90 were 1.7 cc and 92%, respectively. Estimated rate of local control at twelve months was 92%. Three patients (5%) experienced acute grade 2 toxicity. Two patients (4%) continued to suffer from chronic grade 1 skin toxicity at 12 months post-radiotherapy (RT), with an additional two patients (4%) experiencing chronic grade 2 skin toxicity. Forty-nine lesions (92%) were found to have a good or excellent cosmetic outcome with complete tumor remission. CONCLUSIONS: CT-based flap applicator brachytherapy is a valid treatment option for patients with NMSC of the face. This modality offers high rates of local control with acceptable cosmetic outcomes and low rates of toxicity.